DCPH News and Press, Deciphera Pharmaceuticals Inc. From 09/17/20

Deciphera Pharmaceuticals (NASDAQ: DCPH ) announces data from the ovarian cancer cohort in Part 2 of the ongoing Phase 1b/2 study of rebastinib , the selective TIE2 inhibitor, in combination with paclitaxel and from Part 1 of the Phase 1b/2 study of rebastinib in combination with carbop...

- Rebastinib Combined with Paclitaxel Showed Encouraging Preliminary Clinical Benefit and Favorable Tolerability in Patients with Platinum-resistant Ovarian Cancer - - Rebastinib Combined with Carboplatin was Well-tolerated in Patients with Metastatic Solid Tumors and Showed Initial C...

- Results Consistent with Those Presented at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Support Ongoing INTRIGUE Phase 3 Clinical Study in Patients with Second-line GIST - Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announ...

COVID-19 Pandemic BioKangtai (SHZ: 300601), a Guangdong vaccine company, in-licensed rights to develop, manufacture and market AstraZeneca's (AZN) COVID-19 vaccine in China. The candidate is an adenovirus vector-based COVID-19 vaccine that was created by Oxford University and partnered b...

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced that Steve Hoerter, President and Chief Executive Officer, will present at the Canaccord Genuity 40 th Annual Growth Conference on Thursday, August 13, 2020 at 9:00 AM ET. The conference will be held in a virtual meeting format. ...

The following slide deck was published by Deciphera Pharmaceuticals, Inc. in conjunction with this Read more ...

Image source: The Motley Fool. Deciphera Pharmaceuticals, Inc.   (NASDAQ: DCPH) Q2 2020 Earnings Call Aug 4, 2020 , 4:30 p.m. ET Operator Continue reading

Deciphera Pharmaceuticals, Inc. (DCPH) Q2 2020 Earnings Conference Call August 4, 2020, 04:30 PM ET Company Participants Jen Robinson - VP, IR Steve Hoerter - President and CEO Dan Martin - CCO Matt Sherman - CMO Tucker Kelly - CFO Conference Call Participants Chris Ra...

Deciphera Pharmaceuticals (NASDAQ: DCPH ) : Q2 GAAP EPS of -$1.20 beats by $0.17 . More news on: Deciphera Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- QINLOCK TM Approved for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor and U.S. Commercial Launch Underway - - Reported QINLOCK Net Revenue of $4.8 Million in the First Partial Quarter of Launch - - Company Expects to Complete Enrollment in Phase 3 INTRIGUE Study ...